{"type":"trials","record":{"id":21905,"source_id":"clinicaltrials-gov","external_id":"NCT05631236","title":"Promoting Cognitive Resilience and Reducing Frailty in Older Veterans With Bright Light Therapy","brief_summary":"Frailty is a multifactorial syndrome characterized by vulnerability to stressors that is intricately linked to cognitive impairment and mortality risk. Bright light therapy (BLT) reduces circadian disturbances by resynchronizing the hypothalamic biological clock via specific wavelengths of light. Human trials have demonstrated that BLT improves sleep quality and cognitive function in older adults. However, BLT has not been examined for use in older Veteran populations, particularly the impact on frailty. This randomized trial will assess the feasibility of employing BLT to study impacts on frailty, cognition, and sleep in older Veterans. Findings from this pilot will establish the power and effect size necessary for larger trials to support the use of BLT as readily available home-based treatment to improve healthspan of Veterans.","overall_status":"Active Not Recruiting","phases":[],"study_type":"INTERVENTIONAL","sponsor":"VA Office of Research and Development","enrollment":43,"countries":["United States"],"start_date":"2024-01-29","completion_date":"2027-06-30","last_update_date":"2026-07-21","source_url":"https://clinicaltrials.gov/study/NCT05631236","editorial_summary":"A registered study indexed because it matched monitored longevity research terms. Registry status: Active Not Recruiting. Registration does not establish safety or effectiveness.","first_seen_at":"2026-09-24T01:17:12.439005+00:00","last_seen_at":"2026-09-25T06:10:07.378+00:00","metadata":{"sex":"ALL","acronym":"Brite-VET","age_range":"60 Years to 85 Years","comparator":"BLT control; BLT intervention","organization":"VA Office of Research and Development","interventions":["Bright Light Therapy (AYO Glasses)"],"registry_source":"ClinicalTrials.gov","outcome_measures":["Sleep quality — Change from baseline to endpoint at 12 weeks","Short Physical Performance Battery — Change from baseline to endpoint at 12 weeks","Frailty assessment — Change from baseline to endpoint at 12 weeks","Gait speed — Change from baseline to endpoint at 12 weeks","Muscle strength — Change from baseline to endpoint at 12 weeks","Body Composition (Lean and fat mass) — Change from baseline to endpoint at 12 weeks","Interleukin-6 — Change from baseline at 12 weeks","Sleep quantity — Change from baseline at 12 weeks","Step counts — Change from baseline to endpoint at 12 weeks","Cognitive screen - SLUMS — Change from baseline to endpoint at 12 weeks","Brain Derived Neurotrophic Factor (BDNF) — Change from baseline to endpoint at 12 weeks","Sleepiness — Change from baseline at 12 weeks","Fatigue — Change from baseline at 12 weeks","Sleep disorders — Change from baseline at 12 weeks","Amyloid beta 42/40 ratio — Change from baseline at 12 weeks","Cognitive screen - Cognivue — Change from baseline at 12 weeks","Sleep stages — Change from baseline to endpoint at 12 weeks","Phosphorylated tau (P-tau) — Change from baseline at 12 weeks","Interleukin-10 — Change from baseline at 12 weeks","Insomnia — Change from baseline at 12 weeks"],"design_description":"RANDOMIZED · PARALLEL · PREVENTION · SINGLE","source_has_results":false},"controlled_terms":["Veteran Aged 65 and Older","Bright Light Therapy (AYO Glasses)"],"relevance_confidence":100,"source_quality_score":100,"freshness_score":100,"publication_state":"published","match_explanation":"Title contains controlled term: frailty.","quality_checked_at":"2026-09-25T06:10:20.034853+00:00","duplicate_cluster_key":"id:nct05631236","duplicate_of_id":null,"evidence_snapshot":{"status":"structured","version":1,"duration":"2024-01-29 to 2027-06-30","comparator":"BLT control; BLT intervention","confidence":"structured-source","population":"ALL · 60 Years to 85 Years","provenance":{"duration":"start_date and completion_date","comparator":"registry arm fields","population":"registry eligibility fields","intervention":"registry intervention fields","participants":"enrollment","study_design":"study_type and registry design fields","evidence_stage":"phases","reported_outcome":"not available","outcomes_measured":"registry outcome-measure fields"},"generated_at":"2026-09-25T06:10:07.406Z","intervention":["Bright Light Therapy (AYO Glasses)"],"participants":43,"study_design":"RANDOMIZED · PARALLEL · PREVENTION · SINGLE","subject_scope":"Human clinical study registration","evidence_stage":"Phase not reported","safety_context":"Eligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians.","source_support":"Structured registry protocol metadata; no finding-level conclusion is generated.","main_limitation":"This is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.","reported_outcome":null,"outcomes_measured":["Sleep quality — Change from baseline to endpoint at 12 weeks","Short Physical Performance Battery — Change from baseline to endpoint at 12 weeks","Frailty assessment — Change from baseline to endpoint at 12 weeks","Gait speed — Change from baseline to endpoint at 12 weeks","Muscle strength — Change from baseline to endpoint at 12 weeks","Body Composition (Lean and fat mass) — Change from baseline to endpoint at 12 weeks","Interleukin-6 — Change from baseline at 12 weeks","Sleep quantity — Change from baseline at 12 weeks","Step counts — Change from baseline to endpoint at 12 weeks","Cognitive screen - SLUMS — Change from baseline to endpoint at 12 weeks","Brain Derived Neurotrophic Factor (BDNF) — Change from baseline to endpoint at 12 weeks","Sleepiness — Change from baseline at 12 weeks","Fatigue — Change from baseline at 12 weeks","Sleep disorders — Change from baseline at 12 weeks","Amyloid beta 42/40 ratio — Change from baseline at 12 weeks","Cognitive screen - Cognivue — Change from baseline at 12 weeks","Sleep stages — Change from baseline to endpoint at 12 weeks","Phosphorylated tau (P-tau) — Change from baseline at 12 weeks","Interleukin-10 — Change from baseline at 12 weeks","Insomnia — Change from baseline at 12 weeks"],"regulatory_context":"Trial registration is not regulatory approval and does not establish that an intervention is available."},"clinical_trial_topics":[{"topic_slug":"frailty","is_published":true,"match_reasons":["Title contains controlled term: frailty.","Abstract contains controlled term: frailty.","Title supplies longevity context: frailty, frail.","Study type is explicitly identified as INTERVENTIONAL."],"matched_fields":["title","abstract","title context","study type"],"relevance_score":100,"intelligence_topics":{"name":"Frailty","slug":"frailty"}}],"content_sources":{"name":"ClinicalTrials.gov","homepage_url":"https://clinicaltrials.gov/"}},"canonical_url":"https://www.immortal.life/trials/21905","automation_disclosure":"Generated automatically from cited source metadata. No scientist, clinician, researcher, editor, or human reviewer evaluates this publication before release."}